Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 4/20 | 0.34 |
| ▸ | THRA | P10827 | 3/20 | 0.34 |
| ▸ | VDR | P11473 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648470 | 0.85 | F2 (0.36) | F2SMN1; SMN2MEN1CYP3A4CYP2C9 | |
| SCHEMBL6645000 | 0.79 | ALDH1A1 (0.37) | F2SMN1; SMN2ALDH1A1 | |
| SCHEMBL6645363 | 0.74 | IRAK4 (0.34) | F2SMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL6643377 | 0.73 | ALDH1A1 (0.43) | F2GAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6646621 | 0.73 | PKM (0.38) | PKMSMN1; SMN2MEN1CYP2C19KMT2A | |
| SCHEMBL6645980 | 0.73 | TP53 (0.31) | F2 | |
| SCHEMBL6644716 | 0.73 | F2 (0.36) | F2 | |
| SCHEMBL6647719 | 0.67 | F2 (0.31) | F2 | |
| SCHEMBL6644819 | 0.67 | F2 (0.40) | F2PKMSMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL5090319 | 0.66 | MEN1 (0.50) | F2SMN1; SMN2MEN1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | F2 1415/4885GAA 3155/4885THRB 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.